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IRON KINETICS
Part I : Clinical Considerations — Part I I : Methodology
ANDREW T E N PAS, M.D.*, DAVID M . LEAHY, M.S.**,
AND E L L I S J. V A N SLYCK, M.D.*

PART I ; CLINICAL CONSIDERATIONS:

A DYNAMIC PICTURE OF the transport and utilization of iron in normal and disease
states can be obtained by adding small amounts of radioactive iron to the circulation.
Normally when tracer iron ("Fe) is injected intravenously, roughly a quarter of the
dose disappears in ten minutes. The remainder is bound to a beta globulin (transferrin) and clears exponentially from the pla.sma. At first it leaves the plasma rapidly,
approximately 50 per cent leaving in 90 minutes. After 4-8 hours the decrease of
='Fe diminishes progressively, and after two days a second slower exponential rate of
decrease is established which persists for 8-10 days. This pattern indicates a continuous "feedback" of iron from an available source (bone marrow and/or liver)
to the plasma: the so-called "labile iron pool".
The iron movement after it leaves the plasma can be followed by serial counting
over the liver, spleen, and marrow (sacrum). The marrow counts rise to a peak
in about four hours, stay at this level for two days and then decrease rapidly in the
next four days. As the iron leaves the marrow, the counts over liver and spleen
increase and approach the original blood level, indicating that iron is being incorporated
into new red blood cells circulating through these organs.
The 5'Fe appears in the circulating red blood cells in increasing quantities. In
seven to ten days 75 to 85 per cent of the injected iron is found in the red blood
cells and will remain there for about 100 days.
Small quantities of iron added to the circulation by intestinal absorption or by
intravenous injection are used preferentially for red blood cell formation. This implies
that iron is not uniformly mixed throughout the body, and that recently added iron is
more readily available for the metabolic needs than storage iron. This has led to
the concept of the labile iron pool, which has a constant, slow exchange with the
storage iron (ferritin and hemosiderin).
*Division of Hematology.
**Hdsel B. Ford Institute for Medical Research.
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To summarize, the following parameters can be studied with ^'Fe: The rate
of clearance from the plasma, the rate of appearance and degree of incorporation
in the newly formed red blood cells, and the rate of appearance and disappearance
in the liver, spleen, and marrow. Together they elucidate the pathways of iron
transportation and iron metabolism (Figure 1).
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The ^'Fe clears exponentially from the plasma in the first few hours. When the
counts are plotted on semilogarithmic paper, it will give a straight line. In the first
two to five hours, there will be no interference from the "feedback" mentioned
before. When followed for more than two days, a second, slower exponential rate
of disappearance slope appears. In the period of study used clinically (five to six
hours), about 90 per cent of the radioactivity is cleared without deviation of the slope.
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Figure 1
Scheme of the iron cycle with the location where the iron exchange can be studied with radioiron
(S'Fe).

The clearance rate is expressed as the length of time required for one half of
the injected ='Fe to disappear from the circulation. Normally, this half time {TV2)
is 80 to 120 minutes. It is accelerated in iron deficiency anemia, hemolytic anemia,
polycythemia vera, pernicious anemia, and in the anemia associated with infection
and malignancy. The plasma iron clearance rate is decreased in hypoplastic and
myelophthisic marrow states (Figure 2). Under norma] circumstances, the T'/a in
minutes roughly equals the plasma iron concentration.
PLASMA IRON TRANSPORT RATE

(P.l.T.)

The P.l.T. utilizes the rate of plasma clearance, as well as an estimate of the
total transport iron (transferrin) to give a measure of the total amount of iron
leaving the plasma per unit time. Thus, a rapid clearance in the presence of low
circulating iron might yield a transport rate no greater than a much slower clearance
in a subject with a high total plasma iron. The P.l.T. does not measure the rate
of utilization of iron in erythrocyte hemoglobin. This is a separate determination to
be discussed later. Normally, about one third of the iron leaving the plasma returns
from the marrow unused.
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The slope constant of the plasma iron clearance is determined as follows:
Log 2
0.693

W

= Thrs: = 0-^46,

indicating that 34.6 per cent of the total plasma iron is removed per hour. But, as
mentioned before, the P.l.T. also depends on the total iron content of the plasma:
a low value if the plasma iron is low, a high value if the plasma iron is high.
Two methods of calculating the plasma iron transport rate are as follows:
1)

P.l.T. = 0.693 X 24 x serum iron (mg/hter) x plasma volume (liter) = m g . Fe/day
TV2 (in minutes)
or P.l.T. (mg.Fe/day) =
Weight (kg)

2)

mg. Fe/kg/day

P.l.T. = Serum iron (jUg/lOO ml) x 100 - hematocrit = mg. Fe/day/100
TV2 (minutes)
100

Normal values for the plasma iron transport rate (P.l.T.)
in the following ways:

ml. blood

may be expressed

0.61 mg. Fe/day/100 ml. blood.
0.31 — 0.75 mg. Fe/kg./day
40 mg. Fe/day for a 70 kg. man (32-52)

<
2
in

<
J

a.

>
PROLOhOED

>
h
0

PLASMA

IRON

HYPOPLASTIC

<

ANEMIA

MYELOFIBROSIS

o
Q

<(
IT

A C C E L E R A T E D
C L E A R A N C E

P L A S M A

I R O N

IN

IRON
D E F I C I E N C Y
H E M O L Y T I C
D I S O R D E R S
POLYCYTHEMIA
VERA
I N F E C T I O N S
EO

* o

e o

a o

l o o

AND

120

I40

AVERAGE
IRON

N O R M A L

M A L I G N A N C I E S

160

too

200 22O 240

260

TIME (MINUTES AFTER INTRAVENOUS INJECTION OF "Fe)

Figure 2
Plasma clearances of an intravenous tracer dose of radioiron (5'Fe).
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FACTORS INFLUENCING T H E PLASMA IRON TRANSPORT RATE

1. Red cell

destruction:

Increased red cell destruction per se will raise the plasma iron, but does not
significantly affect the plasma iron transport rate unless there is an associated marrow
hyperactivity (see 3c.)
2. Increased body stores of iron:
In hemachromatosis the plasma iron transport rate may be increased as much
as 70 per cent above the normal value. It does not reflect increased red cell
production, but rather reflects accumulation and increased turnover in the liver.
3. Marrow

activity:

a)

Complete arrest of bone marrow: The P.l.T. will be decreased, but not less
than half of the normal rate, reflecting that the turnover in other organs is
about 50 per cent.

b)

Decreased erythropoiesis: The P.l.T. will be decreased.
Example: hypoplastic anemia.

c)

Increased erythropoiesis: The P.l.T. will be increased.
Example: hemolytic disorders.

d)

Ineffective erythropoiesis: As an example, the P.l.T. is increased in pernicious anemia, but the reticulocyte count is low. There is increased heme
formation out of proportion to the rate of blood formation. The P.l.T.
reflects this so-called "ineffective erythropoiesis" or "heme shunt". This
parameter, along with the reticulocyte count, can give a good indication
of an existing block in erythropoiesis.

Ineffective erythropoiesis can also be demonstrated in the sideroachrestic anemias
which show acceleration in the plasma iron clearance with a marked increase of the
plasma iron transport rate. Values as high as 135 mg. Fe/day have been reported.
4. Diurnal variations in plasma iron:
The P.l.T. may be influenced by a diurnal rhythm for obscure reasons. In
general, it has been found that, in about 50 per cent of the cases, the hemostatic
mechanism keeps the P.l.T. constant. In the other 50 per cent, variability in the
P.l.T. has been demonstrated, especially in cases with a rapid turnover.
THE

APPEARANCE OF ='FE I N T H E ERYTHROCYTES ( R . B . C .

UTILIZATION)

The appearance of "Fe in the erythrocytes involves three phases of iron kinetics:
1) plasma iron transport 2) mobility and quantity of iron stores and 3) marrow
function. About 80 per cent of the plasma iron transport serves for immediate red
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blood cell production. Therefore, a high proportion (75-85 per cent) of a given
dose of ='Fe will soon appear in the circulating red blood cells. This can be used
to measure the efficiency of erythropoiesis by calculating the "red cell turnover rate"
as follows:
Plasma iron transport rate (P.l.T.) (mg/day) x maximal uptake tracer in RBC(%)
^00^
=

mg. Fe/day.

Normal values are 30-50 mg. Fe/day (0.43-0.72 mg. Fe/kg./day). However,
there may be some error in measuring the maximal uptake of tracer in the red blood
cells. The plateau is usually reached in 7-10 days, but this is not always true. Also,
there is evidence that after the fifth day tracer from the extramedullary pool also
contributes to the result. It is clear, then, that the fraction utilized for red blood cell
formation cannot be calculated with accuracy under normal conditions. Under
pathological conditions the situation is even more complicated by reutilization from
short-lived erythrocytes or by altered pool kinetics.
These difficulties can be partly avoided by collecting blood samples daily or
every other day for seven to ten days, to determine the radioactivity in the red blood
cells, and to draw up an "appearance curve" (Figure 3). This will indicate not
only the fraction of the original tracer dose appearing (although not very accurately),
but also the rate of appearance which may be helpful under pathological conditions.
RON

DEFICIENCY

POLYCYTHEMIA

O 70 •
UI
N
J

H E M O L Y T I C

VERA

A N E M I A

P A T T E RNS

-«oD
U. S O 9)

PERNICIOUS

A N E M I A

c

H E M O C H R O M A T O S I S

111

UREMIA

0

I N FECTIONS

•

M A L I G N A N C I E S

J

< soK
Z
20IL

H Y P O P L A S T I C

A N E M I A

0
S I D E R O - A C H R E S T I C
AN EMI

A

I z

DAYS

Figure 3
Patterns of appearance of intravenously injected tracer iron (S'Fe) in newly formed red blood cells.
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INTERPRETATION OF THE R E D BLOOD C E L L APPEARANCE CURVE

Two components are of importance: the size of iron stores and the bone
marrow function. The curve will be depressed when the iron stores are increased
even when the erythropoiesis is normal, and conversely, the curve will be elevated
when the iron stores are low. Therefore, with a normal blood production, it reflects
the state of iron storage. When the storage iron is normal, it reflects the rate and
degree of erythropoiesis. Usually, in iron deficiency, the initial utilization is more
rapid than in normals. However, in our experience, the utilization curve is often
depressed. This paradox may be explained by the fact that the amount of ^'Fe used in
the procedure is too small to stimulate the marrow's erythrocyte production from
its dormant state, present in many cases of severe iron deficiency.
The flatness of the curve in infection, malignancy, or uremia is roughly proportional to the severity of these conditions and is an indication of depressed erythropoiesis.
On the other hand, in hemolytic anemia there is a prompt appearance of "Fe in the
red blood cells, but the total utilization is low. This suggests that in hemolytic anemia
the serum iron binding protein is highly saturated with iron from the lysed erythrocytes,
and the injected radioiron is partly deposited in the inactive tissue stores. In some
instances the radioiron is deposited in the spleen, and after splenectomy the utilization
improves. The increased red cell production may show itself by an initial sharp rise
of the appearance curve, only to fall off rapidly because of the short life span of the
erythrocytes (Figure 3).
IN

VIVO COUNTING OVER BODY SITES

In practice, the counters are placed over liver, spleen, and sacrum (marrow),
and the recorded activity is expressed as counts per minute per mc ^'Fe injected.
No great accuracy can be expected. The rate of blood flow through the organs,
anatomical variations, and placement of the counter, all influence the results. For
investigational use the method can be applied as an adjunct to the plasma iron
clearance and the red blood cell appearance of "Fe.
Normally, there will be a sharp rise over the marrow within a few hours after
injection, reaching its peak at about 12 hours. Radioactivity will start to fall off
after one or two days, with a concomitant rise in the counts over the liver and spleen,
approaching the original blood levels.
Several patterns have been described:
Pattern M

= hyperfunction of the marrow with erythroid hyperplasia, resulitng
in an earlier and higher marrow peak.

Pattern O

=

hypofunction of the marrow with erythroid hypoplasia, resulting in
a low marrow count with high counts maintained over the liver
and spleen.
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extramedullary erythropoiesis, which gives an initial temporary high
count over liver and spleen and a low marrow peak. The curve
characteristic of marrow, in this case, appears over liver and spleen.

The iron kinetic patterns in several clinical conditions are outlined in Table I ,
and the following brief case reports serve to show the value of this technique in
unusual clinical circumstances. (Also see Figure 4 ) .
CASE 1: D. B. (#115 94 28). This 23 year old woman received 1500 mg. of
chloramphenicol intravenously after an operative procedure (uterine suspension). Two weeks
later she developed pallor and was found to have widespread petechiae.
Pertinent laboratory data were as follows: Hemoglobin 9.8 gm. per 100 ml., white blood
cell count 150 per cu. mm., reticulocyte count 0.2 per cent, platelet count 67.500 per cu. mm.,
serum iron 131 Mg. per 100 ml. and total iron binding capacity 314 Mg. per 100 ml. The
bone marrow showed few developing cells and was markedly hypocellular. The M:E ratio
was 4:1. The findings suggested aplastic anemia induced by chloramphenicol.
Iron kinetic studies showed an accelerated plasma iron clearance {TVi = 62 minutes)
and a high normal plasma iron transport rate (48.6 mg. Fe/day). The red blood cell
utilization was almost normal (72.3 per cent). These findings were not those of aplastic
anemia, and indeed the patient showed a rapid spontaneous recovery. Within two weeks
the white blood count rose to 6,000 per cu. mm., the platelet count to 617, 500 per cu. mm.,
and the reticulocyte count to 5.4 per cent. The serum iron dropped to 51 Mg. per 100 ml.
In this instance the results of the iron kinetic studies were the earliest indication of the
subsequent marrow recovery.
CASE 2: M.S. (#085 27 81). This 64 year old woman was admitted on August 20,
1964, for investigation of a persistent refractory anemia, present for about 6 months. In
1962, she underwent splenectomy for idiopathic thrombocytopenic purpura, with a good result.
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Figure 4
Observed red blood cell appearance curves of ^'Fe (see text).
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Table I

Nciniuil

Plasma clearance
Tl/2 (minutes)
80-120 minutes

Plasma iron
60-120 Mg-%

Hemolytic
conditions

accelerated

increased

Polycythemia
vera
Secondary
polycythemia
Iron deficiency

accelerated

low

normal

normal

accelerated

low

Pernicious
anemia

accelerated

increased

Hemochromatosis

prolonged

markedly
increased

Sidero-achrestic
anemia
Aplastic anemia

accelerated

increased

prolonged

increased

Myelofibrosis
(agnogenic myeloid
metaplasia)
Infections

normal to
prolonged

Rheumatoid
arthritis

RBC appearance
±50% at 72 hrs.
±80% at 5 days
Steeper than
normal with a
short plateau
Steeper than normal,
90% in 5 days
normal
Steeper than normal;
90% in 5 days, may
be slightly depressed
Normal rate, only
20-50% appearance
at 5-7 days
Low % utilization

increased

Markedly increased-up to
135 mg. Fe/day
50% depression
0.22-0.81 mg. Fe/day/100
ml. blood
2-6X increase

Very low %
utilization
Delay in appearance
and low %
utilization
Low % utilization

accelerated

low to normal

Slightly increased

Normal to low %
utilization

prolonged

low to normal

Increased

Decreased %
utilization

L'reniia
Leukemia

Plasma iron transport
rate (P.l.T.)
40 mg. Fe/day (32-53)
0.61 mg. Fe/day/100
ml. blood
0.31-0.75 mg. Fe/kg/day
0.5-5X increase
2.5 mg. Fe/day/100 ml.
(1.76-4.01)
0-3X increase
1.81 mg. Fe/kg/day average
normal or slightly
increased
normal, slightly
increased or
decreased
50% depression to 6X
increase
0.22-4.0 mg. Fe/day/100
ml. blood
Slightly increased

low to normal
accclcraa-il

low to normal

Normal to slightly
increased

IX-lav in appearance
with low % utilization
Low %
utilization

In vivo counts over
liver, spleen and marrow
Peak over marrow
in 12 hrs. followed
by liver and spleen
peak in 1-2 days.
High counts
over spleen.
Marrow peak earlier
than normal.
normal
Marrow peak
earlier than
normal.
Early marrow
peak followed
by accumulation
over spleen.
High counts over
spleen and liver
maintained.

High counts over
spleen and liver
maintained.
Temporary peak
over spleen and
liver. Marrow low.
Counts may
accumulate over
hver and spleen.
Liver count
maintained higher
than normal.

Counts accumulate
over liver and spleen.
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Admission laboratory data showed: Hemoglobin 6.8 gm. per 100 ml., white blood cell
count 4,250 per cu. mm., platelet count 305,000 per cu. mm., reticulocyte count 7.7 per cent,
serum iron 188 Mg. per 100 ml. and serum iron binding capacity 235 Mg. per 100 ml. A
peripheral smear showed predominantly macrocytic red blood cells. The bone marrow was
hypercellular with an increased normoblastic erythropoiesis (34 per cent).
Iron kinetic studies were as follows: a rapid plasma iron clearance (TVi = 49 minutes)
with an increased plasma iron transport rate (70 mg. Fe/day). The red blood cell utilization
(87.1 per cent) showed a steeper than normal curve with a short plateau. These findings
suggested a hemolytic process.
Further investigations revealed a plasma hemoglobin of 60 mg. per 100 ml. and a
positive test for urine hemosiderin. The diagnosis of paroxysmal nocturnal hemoglobinuria
was confirmed by a positive Crosby test and a positive Hegglin heat resistance test.
CASE 3: A . S. (#088 15 57). This 57 year old man was found to have massive
hepatosplenomegaly in 1958. A diagnosis of agnogenic myeloid metaplasia was made. I n
August, 1964, spelenectomy was considered because of evidence of hemolysis due to
hypersplenism.
Laboratory data showed: Hemoglobin 6.3 gm. per 100 ml., reticulocyte count 5.9 per
cent, platelet count 250,000 per cu. mm., serum iron 133 Mg. per 100 ml., and total iron
binding capacity 332 Mg. per 100 m l .
Iron kinetic studies were done prior to splenectomy. They showed a normal plasma
iron clearance (T'/2 = 86 minutes) and a high normal plasma iron transport rate (50 mg.
Fe/day), but the red blood cell utilization was markedly decereased (35 per cent). These
findings were in keeping with the original diagnosis of myeloid metaplasia.
CASE 4: E. B. (#109 82 03). This 60 year old man was followed since April, 1963,
for a refractory anemia with a hemolytic component. Laboratory data in 1963 showed:
Hemoglobin 8.6 gm. per 100 m., white blood cell count 3,650 per cu. mm., reticulocyte
count 1.5 per cent, total bilirubin 2.4 mg. per 100 ml., serum iron 163 Mg. per 100 ml.,
and total iron binding capacity 247 Mg. per 100 ml. The Coombs' test was negative. The
marrow was hypercellular with an intense normoblastosis, many macronormoblasts, and a
few megaloblasts. ^iCr studies showed a mean red cell hfe of 51.9 days (normal 120 days).
Treatment with hemopoietic agents was unsuccessful. Corticosteroids did not decrease
the rate of hemolysis. Two short courses of 6-mercaptopurine had to be stopped because
of severe leukopenia.
The clinical picture remained unchanged, and the laboratory studies in February, 1965,
showed: Hemoglobin 6.7 gm. per 100 ml., white blood count 2,300 per cu. mm., and
reticulocyte count 0.9 per cent. The red blood cell morphology was pleomorphic with a
moderate hypochromasia. The serum iron was 248 Mg. per 100 ml., and the total iron
binding capacity, 282 Mg. per 100 ml. Marrow studies showed marked hypercellularity with
increased erythropoiesis, incompletely megaloblastic. The M : E ratio was 1:2.
Iron kinetic studies revealed a rapid plasma iron clearance (T'/2 = 45 minutes) with
an enormously increased plasma iron transport rate (197.3 mg. Fe/day). I n contrast the red
blood cell appearance curve was delayed, and the utilization extremely poor (16.3 per cent).
These findings can be explained by the concept of "ineffective erythropoiesis"; in other
words, a rapid iron turnover with a hyperactive marrow, but without the production of an
adequate number of erythrocytes. I t supports the diagnosis of erythremic myelosis in this case.
PART I I : METHODOLOGY
Production o f ^'Fe
(B,y)

•Te (n,7)

'Fe

->• "Co

The above is the (n,7) reaction f o r the production of "Fe by neutron activation.
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Characteristics

"Fe has an approximate half-life of 45 days.
(1)

Beta radiation:

a) B of 0.271 mev. maximum energy
occurring 46%
b) B of 0.462 mev. maximum energy
occurring 54%
c) B of 1.560 mev. maximum energy
occurring 0.3%

(2)

Gamma radiation:

a) a of 0.191 mev. maximum energy
occurring 2.8%
b) a of 1.098 mev. maximum energy
occurring 57%
c) a of 1.289 mev. maximum energy
occuring 43%

Dosage
The usual tracer dose is 10 p.c. of the radioiron, in the chemical form of ferous
citrate.* The radioactivity is contained in 10 ml., with a specific activity of approximately 16 mc./mg. iron.
Radiation

Dosimetry

Assuming counter efficiency
imately 10 fj.c.:
(1)

2.5 X 10^ =
0.25

for "Fe to be 0.25 and administered dose of approx-

1.0 X 10' dis./ min. in whole marrow

dividing by weight of marrow in grams.
(2)

1.0 X 10' =

(3)

3.85 X 10' X 0.12 x 10' ev. = 4.61 x 10' ev./gm./min. or,

(4)

4.61 X 10' x 1.44 X 10' =

(5)

6.64 X 10'° — 0.0013 roentgens equivalent physical per day
" X 10'^

3.85 X 10^ dis./gm./min. or,
6.64 x lO'" ev./gm./day or,

for "Fe, if all activity in erythropoietic areas
= 0.013 rep./day. Then, if one assumes much
of the activity is stored in liver and spleen,
and assuming an even distribution in all three
organs, multiply the calculated bone marrow
radiation dose given above by 0.13.

*Ferrutope — E. R. Squibb and Sons, New Brunswick, New Jersey.
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Procedure
Prior to administration of the radioiron, a fasting blood sample is taken, to be
used as a control and background count. The "Fe is slowly injected into a large
vein in the patient's arm. In order to determine the plasma radioiron disappearance
curve for the patient, 4 ml. of blood are withdrawn at the following time intervals
after injection: 15 minutes, 45 minutes, 75 minutes, and 105 minutes. In order
to determine the total red blood cell utilization of the patient, blood samples are
taken from day 1 to day 10, according to the physician's discretion. These blood
samples are later counted against a standard, prepared from a properly diluted
aliquot of "Fe.

Counting

Techniques

The blood samples taken to determine plasma iron clearance undergo centrifugation, to separate the plasma from the red blood cells. One ml. of plasma is then
accurately pipetted into a screw cap glass vial (1 dram, 15 x 45 mm.). The five
samples, 15 minutes, 45 minutes, 75 minutes, and 105 minutes, and the background
sample are then ready for the direct counting procedure. The blood samples taken
to determine red blood cell utilization are centrifuged, to separate the blood components.
The plasma is then pipetted off and discarded, and one ml. of packed red
blood cells is drawn up and transferred into a glass vial, preparatory to counting.
An "Fe standard is prepared by taking 1 ml. containing 1 p,c./ml. on a known
date, from a standard vial of radioiron. This is then diluted to 100 ml. with
distilled water. One ml. is then taken from this primary dilution and is pipetted
into a screw cap glass vial. This standard is then equal to 0:01 p-C./mX. on a known
date. Decay for the standard is calculated from the date that it was 0.01 p.c. to the
day of injection. The count rate obtained from this standard is used to determine,
in an equation, the amount of radioactivity in the patient's total red blood cell mass.

Instrumentation
The 1 ml. plasma and red blood cell samples containing "Fe are counted using
a scintillation detection system, composed of a N a l ( T l ) well crystal for counting
the gamma radiation, used in conjunction with a Tracerlab SC-71 Compu/Matic
scaler and automatic read-out system. The samples are counted for 10 minutes each,
and a background count is also taken. When the patient's blood is known to contain
radioactive chromium (''Cr), an isotope used in blood volume work, a spectrometer
is interconnected with the detection system. The window width of the spectrometer
is set to discriminate against the ''Cr gammas, picking up only the "Fe photons.
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Calculations
In determining the plasma-iron disappearance curve, the net counts obtained
from the 1ml. plasma samples of 15 minutes, 45 minutes, 75 minutes and 105
minutes are plotted on semilogarithmic paper with time in minutes on the horizontal
axis, and net count rate per 10 minutes on the vertical axis. An extrapolation is
made to time zero from the linear function obtained. The TV2 plasma iron clearance
value is the time required for the plasma count rate to reach one half of the extrapolated count rate at time zero. Examples of plasma iron clearance curves are
illustrated in Figure 2.

In determining the total red blood cell utilization, the hematocrit and normal
blood volume figures must be available, since only 1 ml. of packed red blood cells
counted. Having subtracted the background, the net counts for the packed red
blood cell samples collected over 7-10 days are obtained. The rates now have to
be changed to yield a value for the per cent of iron utilized by the total red cell
mass for that particular day after injection of the radioiron. This value is calculated
by utilizing the following 4 factors: 1) the net count rate of the standard, with its
accurate microcurie level at day of injection (accounting for decay) 2) the net
count rate for the sample, representing the activity in 1 ml. of packed red blood
cells 3) the patient's hematocrit and 4) blood volume. A sample calculation of
per cent iron utilization is as follows:

Day of Injection: 9/23/64
Standard

=

0.01 pc./m\. on 9/23/64

Blood Volume

=

4835 ml.

Hematocrit

— 31%

Sample Net Count

=

Standard Net Count =
Step 1:

0.01
=

:

48135 c/10 min.
9080 c/10 min. (4 days after injection)

48135 — X

:

9080

0.0010 pc./m\. packed red blood cells

Step 2:

4835 x 0.31 =

1499 ml. packed red blood cells

Step 3:

1499 x 0.0019 =

Step 4:

2.85 =

2.85

28.5% utilized by 9/27/64 (4 days after injection)

Examples of red blood cell appearance curves are shown in Figures 3 and 4.
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